News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Stock and bond markets stumble as oil prices surge
*Equity weakness and fixed-income losses coincide with rising crude, signaling investor caution on inflation and growth.*
Anthropic briefs financial regulators on AI security flaws
*Anthropic will present findings from a red-team exercise to global financial watchdogs, flagging cyber vulnerabilities in large language models.*
Extreme weather drives 2-5% swings in hospital admissions
Discovery Health's 10-year study of 3.48M patients shows heat waves increase admissions 2.36% while cold snaps cut them 4.97%, with different lag patterns by condition.
Medicare payment article shows only conference ads, no content
Healthcare IT News published a policy piece containing only event promotions instead of the promised Medicare delivery model analysis.
TEFCA network hits 1B health record exchanges in 16 months
Federal health data exchange network grew from 10M records in early 2025 to nearly 1B today, while officials plan stricter oversight.
Healthcare practice cuts cash cycle from 90 days to 12 days
Televero Behavioral Health eliminated traditional RCM vendors and built an integrated platform that verifies eligibility upfront and collects 90% of payments at service.
Inhibrx shows cancer drug data amid buyout rumors
Biotech company demonstrates its drug may enhance Keytruda's effects while facing acquisition speculation.
GSK licenses hepatitis B drug to China's Sino Biopharmaceutical
The marketing partnership expands GSK's China footprint for bepirovirsen, a therapy central to the company's growth strategy.
Pain drug investment cools as Vertex's Journavx hits $90M in year one
First-year sales fell short of analyst forecasts despite reaching 1M+ prescriptions, raising questions about the commercial ceiling for ion channel blockers.
Bristol Myers strikes $15.2B China drug deal with Hengrui
The pact covers up to 13 drugs and reflects growing ties between Chinese pharma and Western partners.
Rigel takes over Pfizer's Veppanu after Arvinas partnership ends
First-in-class protein degrader drug gets new owner months after approval, settling questions about its commercial future.
Pfizer dumps $1B breast cancer drug for $35M
Pharma giant sells rights to recently approved ARV-471 to Rigel Pharmaceuticals after massive writedown on oncology bet.